This article is more than 5 years old. Information may no longer be current.
VIDEO: Triple therapy with ixazomib significantly improved PFS in patients with multiple myeloma
Click Here to Manage Email Alerts
In this video, Peter Voorhees, MD, director of the myeloma program at the University of North Carolina in Chapel Hill, discusses the results of the Tourmaline-MM1 study, which demonstrated that the addition of ixazomib to lenalidomide and dexamethasone improved PFS for patients with relapsed, refractory myeloma without a substantial increase in toxicity.
The phase 3 Tourmaline-MM1 study from Philippe Moreau, MD, head of hematology at University of Nantes in France, and colleagues enrolled adult patients with relapsed, refractory multiple myeloma who had one to three prior lines of therapy.
Patients treated with ixazomib (Ninlaro, Takeda) experienced significantly longer PFS than patients assigned to the placebo group (20.6 months vs. 14.7 months; HR = 0.74; 95% CI, 0.58-0.93).
The triple therapy expands the available treatment options for patients with multiple myeloma, according to Voorhees.
“For those patients who live very far away from an infusion center or cannot afford logistically to get back and forth for the frequency of carfilzomib infusions, an all-oral regimen with the lenalidomide, dexamethasone and ixazomib is a very nice opportunity,” he said.